Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Business Wire•02/10/2026•10:00 ET
0
Key Highlights
- ➤SPARTAN: 75% achieved complete proteinuria remission after two years
- ➤SPARTAN: eGFR decline averaged 1.1 mL/min/1.73 m² annually
- ➤DUPLEX FSGS: complete remission rates were approximately 3x higher versus irbesartan
- ➤DUPLEX FSGS: kidney failure rates were 75% lower versus irbesartan
- ➤Travere (TVTX) will present nine new FILSPARI data presentations at ASN Kidney Week 2026
Expert Statements
Jula Inrig, Chief Medical Officer of Travere Therapeutics
“The final SPARTAN analysis provides a compelling picture of what's possible when FILSPARI is used as a first-line therapy in IgAN. Over two years, patients experienced high rates of complete proteinuria remission and near physiologic eGFR decline, highlighting the potential for an oral, non-immunosuppressive therapy to address both key treatment goals early in the disease course.”
Jula Inrig, Chief Medical Officer of Travere Therapeutics
“In FSGS, the DUPLEX analysis adds to the evidence supporting the use of FILSPARI for patients without nephrotic syndrome, with higher complete proteinuria remission rates and lower observed rates of kidney failure compared to irbesartan. Together, these data reinforce the clinical value of FILSPARI across two rare, progressive kidney diseases.”
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgAN
Get started
Create a free account to read the full story.